HI
BCTX

Harbour Investments’s Briacell Therapeutics BCTX Stock Holding History

Harbour Investments’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1
Closed -$1K – 2708
2021
Q3 		$1K Hold
1
– – ﹤0.01% 3438
2021
Q2 		$1K Hold
1
– – ﹤0.01% 3493
2021
Q1 		$1K Buy
+1
New +$544 ﹤0.01% 3325

Other funds holding BCTX

LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
IA
Insight Advisors Newtown, Pennsylvania $567M AUM 25.52% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return

Harbour Investments's BCTX Position: Q4 2021 in Review

Harbour Investments sold out of Briacell Therapeutics (BCTX) in Q4 2021, closing a stake of 1 share — an estimated $1K sold.

Harbour Investments first reported a position in BCTX in Q1 2021 and held it in 3 quarters. The position peaked at $1K in Q3 2021. 18 funds tracked by Wall St. Rank hold BCTX as of Q4 2021.

  • Harbour Investments reported no remaining Briacell Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Harbour Investments sold 1 Briacell Therapeutics share in Q4 2021, an estimated $1K.
  • Harbour Investments first reported a position in Briacell Therapeutics in Q1 2021 and held it in 3 quarters.
  • Harbour Investments's Briacell Therapeutics position peaked at $1K in Q3 2021.
  • 18 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2021.

Based on Harbour Investments's 13F filing for Q4 2021, filed 16 Feb 2022.